SenesTech Inc. Common Stock (SNES)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn good returns on capital and sell below intrinsic value. SenesTech does not fit that mold today. It sells ContraPest and Evolve, fertility-control baits for rats and mice, but the figures show a commercial story still far from self-funding. In fiscal 2025, revenue was $2.2 million and net loss was $6.4 million; in fiscal 2024, revenue was $1.9 million and net loss was $6.2 million; in fiscal 2023, revenue was $1.2 million and net loss was $7.7 million. The latest filed quarter, fiscal Q2 2026 ended 2026-06-30, had revenue of $770,000 and net loss of $1.8 million. Free cash flow for the trailing twelve months was negative $6.7 million, a FairStock calculation, against a $3.4 million market cap. The FairStock price-to-book is 0.55 and P/E is negative 1.03 at the 2026-10-13 close, which might look statistically cheap, but ROE of -107.41% and ROCE of -45.55% show capital is being consumed, not compounded. The FairStock Altman Z-score of -20.98 and Piotroski score of 4/9 reinforce fragility. FairStock's Lynch category is 'none' because the company lost money in each of the last four years. The niche might have potential, and revenue did rise from fiscal 2024 to fiscal 2025, but with no evident moat and heavy cash use, this is speculative, not a Graham-style bargain.

In plain English: SenesTech makes fertility-control baits to help control rat and mouse populations. The business is still tiny and unprofitable, with losses in each of the last four years and cash burn that is large next to its $3.4 million market value. At $0.63 on 2026-10-13, the price looks low against its accounting value, but the weak profits make it hard to call clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer